Synopsis: Sean Bohen is the President and CEO of Olema Oncology, a company dedicated to developing targeted therapies for women with breast cancer. An oncologist by training, Dr. Bohen has a background in big pharma, having worked at Genentech and AstraZeneca before joining Olema. He talks with host Rahul Chaturverdi about the differences between working for biotech and big pharma companies, the work his team is pursuing at Olema, the opportunities and challenges within the breast cancer landscape, the ups and downs of running a biotech company and managing a team with the current market dynamics, and the importance of partnerships and how they can strength companies. Biography: Dr. Bohen has served as Chief Executive Officer of Olema Oncology and a member of the Board of Directors since September 2020. He is also a non-executive director of Gyroscope Therapeutics, Ltd. and AltruBio, Inc. He has extensive oncology drug development experience, having served as Executive Vice President, Global Medicines Development, and Chief Medical Officer at AstraZeneca PLC. Before that, he held a number of senior leadership roles at Genentech, Inc., including Senior Vice President, Early Development, Genentech Research and Early Development. Prior to Genentech, he was a Clinical Instructor in Oncology at Stanford University School of Medicine; a research associate at the Howard Hughes Medical Institute; and a postdoctoral fellow at the National Cancer Institute (NCI). Dr. Bohen received a B.S. in bacteriology from the University of Wisconsin-Madison, and a Ph.D. in biochemistry and biophysics and an M.D. from the University of California, San Francisco.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related